Aptevo Therapeutics Inc. fell 14.7% on Tuesday, October 27, 2026, on 80,600 shares. Headlines around the move:
Aptevo Therapeutics Inc. (APVO:NASDAQ) closed at $1.35 on November 2, 2026, up 0.75% on the day. The stock trades 95.2% below its 52-week high of $28.08 and 7.7% above its 52-week low of $1.25. Over the past year, it lost 94.9%. Aptevo Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 31, 2025, APVO closed higher on 104 days (41%). Its best day was January 7, 2026 (+12.01%) and its worst was December 26, 2025 (-34.73%). The stock moved 10% or more in a single session 19 times. It opened at least 5% above the previous day's high 1 time.
Aptevo Therapeutics Inc., a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company's marketed products also comprise VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals; and IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates include MOR209/ES414, ES210, ES425, and otlertuzumab used to expand on the utility and effectiveness of therapeutic antibodies; and 5E3 mAb, a monoclonal antibody therapeutic that is in pre-clinical development for Alzheimer's disease. The company was incorporated in 2016 and is based in Seattle, Washington. As of August 01, 2016, Apt...
Find more stocks like APVO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.